Homepage Featured News
August 5, 2024
FDA Approves Blood Test for Colon Cancer Detection
July 5, 2023
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan
May 31, 2023
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance
May 17, 2023
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers
May 16, 2023
Guardant Health Releases Inaugural ESG Report
The publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy